查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1542950

全球造影劑市場 - 2024-2031

Global Contrast Agents Market - 2024-2031
出版日期: | 出版商: DataM Intelligence | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

報告概述

全球造影劑市場在 2023 年達到 62 億美元，預計到 2031 年將達到 98.6 億美元，2024-2031 年預測期間複合年成長率為 6.1%。

造影劑（或造影劑）可增加醫學影像中體內結構或液體的對比。造影劑吸收或改變外部電磁或超音波，這與發射輻射的放射性藥物不同。造影劑是一組化學試劑，旨在透過提高成像模式的對比度解析度來幫助表徵病理學。已經針對每種結構成像方式和每種可能的給藥途徑開發了特定的造影劑。

硫酸鋇造影劑已經使用了幾十年，並且是公認的用於檢查胃腸道的口服製劑。它們的使用通常僅限於放射線照相和螢光鏡檢查。碘造影劑是用於放射線照相、透視、血管造影和 CT 成像的主要造影劑。它們是一組用途廣泛的藥物，用於靜脈注射、口服和其他給藥途徑，例如尿道和關節內給藥。

市場動態：

司機

放射學和診斷中心數量的增加以及放射學和診斷領域的進步

全球造影劑市場的需求是由多種因素所驅動的。放射學和診斷中心數量的增加是造影劑市場的主要促進因素之一。人們對各種診斷和放射學程序的認知不斷提高也導致了市場的成長。

根據醫療保健半徑，印度診斷影像市場預計未來五年複合年成長率（CAGR）為12-15%。這個數字高於全球 5% 的複合年成長率。慢性病盛行率的上升、影像技術的採用增加以及老年人口的增加預計將推動這一成長。

慢性病、心血管疾病、基因突變和胃腸道疾病發病率的增加預計都會對該行業產生積極影響。醫療保健領域支出的增加和消費者意識的提高也將推動成像和放射學行業的發展。

限制

全球造影劑市場的主要限制之一是與造影劑使用相關的副作用和過敏反應。在診斷過程中，少數人會觀察到副作用，這會對身體造成負面影響。根據 NIH 發表的一篇文章，非離子造影劑立即反應的發生率範圍為 0.01-0.04%（重度）到 3%（輕度）。非離子製劑的風險較小。

另一個限制是由於成像程序的進步而導致的高成本。高昂的成本限制了造影劑在某些人群中的使用。

細分市場分析

全球造影劑市場根據類型、應用、模式、最終用戶和地區進行細分。

分段CT掃描佔全球造影劑市佔率約48.7%

CT掃描過程中廣泛使用顯影劑。 Computed tomography scan (CT or CAT scan) is a non-invasive diagnostic imaging procedure that uses a combination of special X-ray equipment and sophisticated computer technology to produce cross-sectional images (often called slices), both horizontally and vertically, of the身體.然後可以在電腦顯示器上檢查或列印所研究區域的這些橫斷面影像。

CT掃描中使用的造影劑的主要成分是碘。 CT造影劑有離子型和非離子型兩種。目前，CT掃描中應用最廣泛的是非離子造影劑。根據傑斐遜放射學的說法，使用造影劑的 CT 掃描廣泛用於可視化內部結構，如骨骼、血管和器官。它們在檢測腫瘤、血管疾病和內出血方面特別有用。

例如，2022 年7 月，費森尤斯·卡比(Fresenius Kabi) 宣布將在美國推出一系列學名藥造影劑產品組合，首先推出碘克沙醇注射液(USP)，該產品被美國食品和藥物管理局(FDA) 列為全國緊缺。碘克沙醇注射 (USP) 是美國 FDA 批准的第一種通用等滲二聚碘造影劑，用於基於 X 光的診斷成像，例如電腦斷層掃描 (CT) 掃描。

市場地理分析

北美約佔全球造影劑市場佔有率的49.2%

預計北美地區將在預測期內佔據最大的市場佔有率。該地區放射學和診斷中心數量的增加以及人們意識的提高有助於推動市場發展。

由於北美地區存在主要參與者，它在診斷和放射學程序方面取得了進展。長期疾病和複雜合併症發病率上升以及私人和當局費用增加等因素預計將推動北美汽油市場的成長

例如，2024 年 1 月，凱斯西儲大學的科學家開始研究開發以人工智慧為基礎的化學影像造影劑替代品。 CWRU 最近從美國國家科學基金會獲得了為期四年、價值 112.5 萬美元的資助，以幫助推動其工作。他們正在盡最大努力在 CT、MR 和 X 光檢查期間創建一種新方法，在不注射钆等物質的情況下增強影像。

目錄

第 1 章：方法與範圍

第 2 章：定義與概述

第 3 章：執行摘要

第 4 章：動力學

  • 影響因素
    • 促進要素
      • 增加放射學和診斷中心的數量
      • 診斷領域的進步
      • 全球人口中慢性病數量的增加

第 5 章：限制

  • 造影劑成本高
  • 與使用顯影劑相關的副作用

第 6 章：機會

第 7 章：影響分析

第 8 章：產業分析

  • 波特五力分析
  • 供應鏈分析
  • 定價分析
  • 監管分析
  • 未滿足的需求
  • PESTEL分析
  • 專利分析
  • SWOT分析

第 9 章：按類型

  • 鋇對比劑
  • 碘造影劑
  • 钆基造影劑
  • 微泡造影劑
  • 其他

第 10 章：按申請

  • 腫瘤學
  • 心臟病學
  • 神經病學
  • 其他

第 11 章：按形態

  • X光/CT
  • 核磁共振成像
  • 超音波
  • 其他

第 12 章：最終用戶

  • 醫院
  • 專科診所
  • 診斷中心
  • 其他

第 13 章：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 歐洲其他地區
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地區
  • 亞太
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 中東和非洲

第14章：競爭格局

  • 競爭場景
  • 市場定位/佔有率分析
  • 併購分析

第 15 章：公司簡介

  • Bayer AG
    • 公司概況
    • 產品組合和描述
    • 財務概覽
    • 主要進展
  • GE Health Care
  • Bracco diagnostics Inc.,
  • Lantheus Medical Imaging
  • Nano Therapeutics Pvt Ltd.
  • Unijules Life Sciences Ltd.,
  • Guerbet SA
  • Trivitron Healthcare
  • Spago Nanomedical AB
  • Taejoon Pharma (*LIST NOT EXHAUSTIVE)

第 16 章：附錄

簡介目錄
Product Code: MD99

Report Overview

The Global Contrast Agents Market reached US$ 6.2 billion in 2023 and is expected to reach US$ 9.86 billion by 2031, growing at a CAGR of 6.1% during the forecast period 2024-2031.

A contrast agent (or contrast medium) increases the contrast of structures or fluids within the body in medical imaging. Contrast agents absorb or alter external electromagnetism or ultrasound, which differs from radiopharmaceuticals, which emit radiation. Contrast agents are a group of chemical agents developed to aid in the characterization of pathology by improving the contrast resolution of an imaging modality. Specific contrast agents have been developed for every structural imaging modality and every conceivable route of administration.

Barium sulfate contrast media have been used for many decades, and are well-established as oral agents for the examination of the GI tract. Their use is generally restricted to radiographic and fluoroscopic examinations. Iodinated contrast media are the mainstay contrast agents for use in radiographic, fluoroscopic, angiographic, and CT imaging. They are a versatile group of agents used for intravenous, oral, and other routes of administration, such as urethral and intra-articular.

Market Dynamics: Drivers

The rise and increase in the number of radiology and diagnostic centers and advancements in the field of radiology and diagnostics

The demand for the global contrast agents market is driven by multiple factors. The rise and increase in the number of radiology and diagnostic centers is one of the major driving factors in the contrast agents market. The increased awareness among people about various diagnostic and radiology procedures also leads to an increase in the market.

According to the healthcare radius, the Indian diagnostic imaging market is expected to register a compounded annual growth rate (CAGR) of 12-15 percent over the next five years. This number is greater than the global CAGR rate which is pegged at five percent. The rise in prevalence of chronic diseases, increased adoption of technologies in imaging, and a growing elderly/geriatric population are expected to boost the growth.

The increasing incidences of chronic diseases, cardiovascular disorders, genetic mutations, and GI disorders are all expected to impact the industry positively. Increased expenditure on the healthcare sector and greater consumer awareness will also give an impetus to the imaging and radiology industry.

Restraints

One of the major restraints in the global contrast agents market is the side effects and allergic reactions that are associated with the usage of contrast agents. In a few people during the diagnostic procedures, side effects are observed which causes a negative impact on the body. According to an article published by NIH, the incidence of immediate reactions to non-ionic contrast media ranges from, 0.01-0.04%(severe) to 3%(mild). Non-ionic agents are associated with less risk.

Another restraint is the high cost due to advancements in imaging procedures. The high cost limits the usage of contrast agents to certain segments of people.

Market Segment Analysis

The global contrast agents market is segmented based on type, application, modality, end-user, and region.

The segment CT scan accounted for approximately 48.7% of the global contrast agents market share

The contrast agents are widely used in the procedure of CT scans. Computed tomography scan (CT or CAT scan) is a non-invasive diagnostic imaging procedure that uses a combination of special X-ray equipment and sophisticated computer technology to produce cross-sectional images (often called slices), both horizontally and vertically, of the body. These cross-sectional images of the area being studied can then be examined on a computer monitor or printed.

The main component of the contrast material used in the CT scan is iodine. The CT contrast agents are of two types: ionic and non-ionic. At present, in CT scans the non-ionic contrast agents are most widely used. According to Jefferson radiology, CT scans with contrast agents are widely used to visualize internal structures such as bones, blood vessels, and organs. They are particularly useful in detecting tumors, vascular diseases, and internal bleeding.

For instance, in July 2022, Fresenius Kabi announced that it would introduce a portfolio of generic contrast media agents in the United States, starting immediately with the launch of Iodixanol Injection, USP, a product the U.S. Food and Drug Administration (FDA) lists as being in shortage nationwide. Iodixanol Injection, USP is the first U.S. FDA-approved generic iso-osmolar, dimeric iodinated contrast media agent, which is used during diagnostic x-ray-based imaging such as computed tomography (CT) scans.

Market Geographical Analysis

North America accounted for approximately 49.2% of the global contrast agents market share

North America region is expected to hold the largest market share over the forecast period. The increase in the number of radiology and diagnostic centers, and growing awareness among people, in this region, help to propel the market.

Due to the presence of major players in the region of North America, it has advancements in diagnostic and radiology procedures. Factors including the rising incidence of long-term sicknesses and complicated comorbidities and increasing private and authority fees are expected to gasoline market increase in the North U.S.

For instance, in January 2024, Scientists with Case Western Reserve University started researching and working on the development of an artificial intelligence-based alternative to chemical imaging contrast agents. CWRU recently scored a four-year, $1.125 million grant from the National Science Foundation to help fuel its work. They are working their best to create a new approach during CT, MR, and X-ray exams, enhancing images without injecting substances such as gadolinium.

Market Segmentation

By Type

  • Barium-based contrast media
  • Iodinated contrast media
  • Gadolinium-based contrast medium
  • Microbubble-based contrast media

By Application

  • Oncology
  • Cardiology
  • Neurology
  • Others

By Modality

  • X-Ray / CT
  • MRI
  • Ultrasound
  • Others

By End-User

  • Hospitals
  • Specialty Clinics
  • Diagnostic Centers
  • Others

By Region

  • North America
  • The U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Rest of Europe
  • South America
  • Brazil
  • Argentina
  • Rest of South America
  • Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
  • Middle East and Africa

Market Competitive Landscape

The major global players in the global contrast agents market include Bayer AG, GE Health care, Bracco Diagnostics Inc., Lantheus Medical Imaging, Inc., Nano Therapeutics Pvt Ltd., Unijules Life Sciences Ltd., Guerbet SA, Trivitron Healthcare, Spago Nanomedical AB, Taejoon Pharma among others.

Key Developments

  • In September 2022, Bracco Diagnostics Inc., the United States (U.S.) subsidiary of Bracco Imaging S.p.A., an innovative world leader in diagnostic imaging, announced that the U.S. Food and Drug Administration (FDA) has approved Gadopiclenol Injection, a new, highly stable macrocyclic gadolinium-based contrast agent (GBCA), which shows the highest relaxivity compared to all the other GBCAs available today in the United States.
  • In February 2023, Guerbet, a global leader in medical imaging with more than 30 years of experience in MRI, announced the commercial launch and dosing of the first patient with Elucirem(TM) (gadopiclenol) injection following FDA approval in 2022. This next-generation GBCA from Guerbet, a highly stable macrocyclic gadolinium-based contrast agent (GBCA), has the highest relaxivity in its class for magnetic resonance imaging (MRI) and is indicated for use in adults and children aged 2 years and older.

Why Purchase the Report?

  • To visualize the global contrast agents market segmentation based on type, application, modality, end-user, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of global contrast agents market level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping is available in Excel consisting of key products of all the major players.

The global contrast agents market report would provide approximately 78 tables, figures, and 181 Pages.

Target Audience 2024

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by Application
  • 3.3. Snippet by Modality
  • 3.4. Snippet by End-User
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing the number of radiology and diagnostic centers
      • 4.1.1.2. Advancements in the field of diagnostics
      • 4.1.1.3. Increase in the number of chronic diseases in the global population

5. Restraints

  • 5.1. High cost of the contrast agents
  • 5.2. Side effects associated with usage of contrast agents

6. Opportunity

7. Impact Analysis

8. Industry Analysis

  • 8.1. Porter's Five Force Analysis
  • 8.2. Supply Chain Analysis
  • 8.3. Pricing Analysis
  • 8.4. Regulatory Analysis
  • 8.5. Unmet Needs
  • 8.6. PESTEL Analysis
  • 8.7. Patent Analysis
  • 8.8. SWOT Analysis

9. By Type

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.1.2. Market Attractiveness Index, By Type
  • 9.2. Barium based contrast media*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Iodinated contrast media
  • 9.4. Gadolinium-based contrast media
  • 9.5. Microbubble-based contrast media
  • 9.6. Others

10. By Application

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.1.2. Market Attractiveness Index, By Application
  • 10.2. Oncology*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Cardiology
  • 10.4. Neurology
  • 10.5. Others

11. By Modality

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 11.1.2. Market Attractiveness Index, By Modality
  • 11.2. X-Ray / CT*
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 11.3. MRI
  • 11.4. Ultrasound
  • 11.5. Others

12. By End-User

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 12.1.2. Market Attractiveness Index, By End-User
  • 12.2. Hospitals*
    • 12.2.1. Introduction
    • 12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 12.3. Specialty Clinics
  • 12.4. Diagnostic Centers
  • 12.5. Others

13. By Region

  • 13.1. Introduction
    • 13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 13.1.2. Market Attractiveness Index, By Region
  • 13.2. North America
    • 13.2.1. Introduction
    • 13.2.2. Key Region-Specific Dynamics
    • 13.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 13.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 13.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 13.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 13.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.2.7.1. The U.S.
      • 13.2.7.2. Canada
      • 13.2.7.3. Mexico
  • 13.3. Europe
    • 13.3.1. Introduction
    • 13.3.2. Key Region-Specific Dynamics
    • 13.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 13.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 13.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 13.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 13.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.3.7.1. Germany
      • 13.3.7.2. UK
      • 13.3.7.3. France
      • 13.3.7.4. Italy
      • 13.3.7.5. Spain
      • 13.3.7.6. Rest of Europe
  • 13.4. South America
    • 13.4.1. Introduction
    • 13.4.2. Key Region-Specific Dynamics
    • 13.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 13.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 13.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 13.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 13.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.4.7.1. Brazil
      • 13.4.7.2. Argentina
      • 13.4.7.3. Rest of South America
  • 13.5. Asia-Pacific
    • 13.5.1. Introduction
    • 13.5.2. Key Region-Specific Dynamics
    • 13.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 13.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 13.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 13.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 13.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.5.7.1. China
      • 13.5.7.2. India
      • 13.5.7.3. Japan
      • 13.5.7.4. South Korea
      • 13.5.7.5. Rest of Asia-Pacific
  • 13.6. Middle East and Africa
    • 13.6.1. Introduction
    • 13.6.2. Key Region-Specific Dynamics
    • 13.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 13.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 13.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 13.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

14. Competitive Landscape

  • 14.1. Competitive Scenario
  • 14.2. Market Positioning/Share Analysis
  • 14.3. Mergers and Acquisitions Analysis

15. Company Profiles

  • 15.1. Bayer AG*
    • 15.1.1. Company Overview
    • 15.1.2. Product Portfolio and Description
    • 15.1.3. Financial Overview
    • 15.1.4. Key Developments
  • 15.2. GE Health Care
  • 15.3. Bracco diagnostics Inc.,
  • 15.4. Lantheus Medical Imaging
  • 15.5. Nano Therapeutics Pvt Ltd.
  • 15.6. Unijules Life Sciences Ltd.,
  • 15.7. Guerbet SA
  • 15.8. Trivitron Healthcare
  • 15.9. Spago Nanomedical AB
  • 15.10. Taejoon Pharma (*LIST NOT EXHAUSTIVE)

16. Appendix

  • 16.1. About Us and Services
  • 16.2. Contact Us